Journal of Medicinal Chemistry · 2020 · 120 citations · 17 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryMolecular PharmacologyCovalent Inhibitor DesignLigand BindingCell Line-derived Xenograft ModelsChemical Structure-activity RelationshipsCovalent Enzyme InhibitorsCovalent InhibitorsHistone Demethylase InhibitionHistone DemethylasesLysine-targeted InhibitorsMonoamine Oxidases
Histone demethylase LSDl (KDMlA) belongs to the flavin adenine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammalian biology. Dysregulation and overexpression of LSD1 are hallmarks of a number of human diseases, particularly cancers that are characterized as morphologically poorly differentiated. As such, inhibitors of LSD1 have potential to be beneficial as a cancer therapy. The most clinically advanced inhibitors of LSDl are covalent inhibitors derived from tranylcypromine (TCP). Herein, we report the discovery of a novel series of reversible and selective LSDl inhibitors. Exploration of structure-activity relationships (SARs) and optimization of ADME properties resulted in the identification of clinical candidate CC-90011. CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived xenograft (PDX) SCLC models. CC-90011 is currently in phase 2 trials in patients with first line, extensive stage SCLC (ClinicalTrials.gov identifier: NCT03850067).
17
Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1
Yujiang Geno Shi, Yujiang Geno Shi, Fei Lan et al. · Cell · 2004 · 4K citations · Full text
David B. Sykes, Youmna Kfoury, François Mercier et al. · Cell · 2016 · 488 citations · Full text
Medicine, Oncology, Pharmacology +14